Get the Weekly Intelligence Brief — top committee picks every Sunday.
MANE · NYSE · STOCK

Veradermics, Incorporated

Healthcare Updated August 11, 2026
$108.67
52W $32.00 – $131.24
60/100
$4.55B
-69.8
1.35
AI Committee Verdict
Buy
60/100
Conviction: Contested · 50% agreement · 4 analysts
Contested

Is MANE Bullish or Bearish?

Bullish. Innellis AI committee rates Veradermics, Incorporated (MANE) Buy with a composite score of 60/100 , based on 4 analysts with 50% agreement. Last updated August 11, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +15.31 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -4.69 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 17.4% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
  • Trend and market structure agree -- coherent bullish picture — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • Bollinger bandwidth of 17.4% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 11, 2026
Overall Committee Score
60/100
Agreement
50%
Analysts
4
Conviction
Contested
Sector Rank
Top 50%
of 192 Healthcare peers
Technical Analyst bullish
69 / 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
Risk Analyst bearish
35 / 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 17.4% signals elevated volatility
Macro Analyst bullish
78 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst neutral
58 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager neutral
55 / 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Open Full Terminal →

Technical Analysis

RSI (14)
47.9
Neutral
MACD Histogram
0.009
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Support
$87.48
Resistance
$116.29
Bollinger %B
0.44
Inside Bands
Price vs Moving Averages
EMA 9
$109.47 Below
EMA 21
$109.95 Below
EMA 50
$106.91 Above
EMA 200
$78.40 Above

Fundamental Analysis

Valuation
67
Profitability
25
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio -69.8×
P/B Ratio 10.38×
PEG Ratio -0.70
Dividend Yield 0.00%
52W High $131.24
52W Low $32.00
Quality & Growth
ROE 5784.0%
ROA -4586.3%
Gross Margin 0.0%
Operating Margin 0.0%
Revenue Growth YoY
Debt / Equity 0.00
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -69.8 (inexpensive relative to a 15-40x range); Price-to-book of 10.4x; PEG ratio of -0.7 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 57.8%; Return on assets of -45.9%; Net margin of 0.0%; Gross margin of 0.0%; Current ratio of 59.12 (healthy short-term liquidity); Debt-to-equity of 0.00; Free cash flow per share is negative (-1.20); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full MANE Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore MANE Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime